Efficacy of Cryopreserved Recombinant Alteplase for Declotting Thrombosed Central Catheters

Abstract

Get full access to this article

View all access options for this article.

References

Important drug warning. January 25, 1999. The Food and Drug Administration [cited 1999 Oct 13]. Available at: URL: http://www.fda.gov/cber/ltr/abb012599.htm.

ASHP technical assistance bulletin on quality assurance for pharmacy-prepared sterile products. Am J Hosp Pharm 1993;50: 2386–98.

Gale

O'Connor

Chu

Stanley

. Restoring patency of thrombosed catheters with cryopreserved urokinase. JPEN J Parenter Enteral Nutr 1984;8: 298–9.

Atkinson

Bagnall

Gomperts

. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters. JPEN J Parenter Enteral Nutr 1990;14: 310–1.

Haire

Atkinson

Stephens

Kotulak

. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: A double-blinded, randomized trial. Thromb Haemost 1994;72: 543–7.

Package insert. Abbokinase Open-Cath (urokinase). North Chicago, IL: Abbott Laboratories, August 1994.

Callis

Cullinane

Horne

III . Bioactivity of cryopreserved alteplase solutions. Am J Health Syst Pharm 1999;53: 2056–7.